Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

IN10018 Terapia di combinazione nel NSCLC avanzato con mutazione EGFR

9 novembre 2026 aggiornato da: InxMed (Shanghai) Co., Ltd.

Uno studio clinico multicentrico, in aperto, di fase Ib/II per valutare la sicurezza, la tolleranza, la farmacocinetica e l'efficacia antitumorale di IN10018 in combinazione con EGFR-TKI di terza generazione in pazienti con NSCLC avanzato positivo alla mutazione dell'EGFR

This is a multicenter, open-label, phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics and antitumor efficacy of IN10018 in combination with third-generation EGFR-TKI (Furmonertinib is the proposed) in previously-treated or naïve advanced EGFR-mutation positive NSCLC.

Panoramica dello studio

Stato

Attivo, non reclutante

Condizioni

Descrizione dettagliata

This study includes 2 parts: Phase Ib-Dose Confirmation and Phase II-Dose Expansion. And 3 cohorts are set up in this study as cohort 1 to enroll subjects currently accepting third-generation EGFR-TKI (Furmonertinib is proposed) as first-line treatment, cohort 2 to enroll subjects who previously accepted third-generation EGFR-TKI treatment and 1-2 lines chemotherapy, and cohort 3 to enroll treatment-naive advanced EGFR mutation-positive NSCLC subjects.

The phase Ib-dose confirmation part will be conducted in cohort 2 and aim to determine the recommended phase II dose (RP2D) of IN10018 in combination with Furmonertinib. Phase II-Dose Expansion part will be conducted in cohort 1-3 and further explore the antitumor efficacy, safety and PK of IN10018 in combination with Furmonertinib in subjects with previously-treated or naïve advanced EGFR mutation-positive NSCLC.

Tipo di studio

Interventistico

Iscrizione (Stimato)

110

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Shanghai, Cina
        • Shanghai Pulmonary Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria

  1. Be able to understand and be willing to sign informed consent.

  2. Male or female aged ≥ 18 years old at the time of signing informed consent.

  3. Histologically or cytologically confirmed locally advanced or metastatic NSCLC, who is not suitable for radical surgery or radiotherapy.

  4. Documented EGFR mutations known to be associated with EGFR-TKI sensitivity, including Ex19del or L858R. Except for EGFR-TKI sensitive mutation, coexisting with other EGFR mutation types such as T790M can be allowed.

  5. Prior systemic antitumor therapy allowed are listed as follows:

    • Cohort 1: Subjects who are on the treatment of Furmonertinib as the first-line treatment setting.
    • Cohort 2: Subjects failed in third-generation EGFR-TKI treatment and also failed in or were intolerant to 1-2 lines of chemotherapy.
    • Cohort 3: subjects who haven't accepted any systemic therapy before. Prior adjuvant or neoadjuvant chemotherapy is permitted if an interval from the lost dose of adjuvant or neoadjuvant chemotherapy to the first documented PD is >6 months.
  6. Measurable lesions at baseline according to RECIST 1.1 criteria.

  7. Has an ECOG performance status of 0 or 1.

  8. Estimated life expectancy is more than 3 months.

  9. Adequate bone marrow, liver, renal, and coagulation function within 7 days prior to the first dose of study treatment/randomization.

Exclusion Criteria

  1. Have experienced major surgical procedures or major trauma within 28 days prior to the first dose of study treatment/randomization.

  2. Have received the following prior systemic antitumor therapy:

    • Cohort 1: Have received chemotherapy, target therapy besides Furmonertinib, immunotherapy, biological therapy, and other antitumor drugs.
    • Cohort 2: Have received chemotherapy, targeted therapy, immunotherapy, biological therapy, and other antitumor drugs within 28 days prior to the first dose of study treatment.
    • Cohort 3: Have received systemic antitumor therapy for locally-advanced or metastatic NSCLC including chemotherapy, target therapy, immunotherapy, biotherapy, etc.
  3. Cohort 2 only: Presence of other gene mutations, including ALK mutation, MET amplification, HER2 amplification, RAS mutation, etc. after progression on prior third-generation EGFR-TKI treatment.

  4. Cohort 3 only:Has received the treatment of EGFR-TKI。

  5. Prior FAK inhibitors treatment.

  6. Have received systemic administration of potent inhibitors/inducers of CYP3A4, or P-gp inhibitors within 14 days prior to the first dose of treatment/randomization or are expected to receive systemic administration of these drugs during study treatment.

  7. Has received radiotherapy for study disease or radiotherapeutic area covered for more than 30% of the bone marrow within 28 days prior to the first dose of study treatment/randomization.

  8. Has had interstitial lung disease (ILD), drug-induced ILD, radiation pneumonia requiring steroid therapy; or diagnosis of clinically active ILD during the screening period.

  9. Has a prior history of other malignancy within 3 years prior to signing informed consent.

  10. Has known symptoms of spinal cord compression, active central nervous system (CNS) metastases, and/or carcinomatous meningitis.

  11. Has a history of severe cardiovascular or cerebrovascular diseases within 6 months prior to the first dose of study treatment/randomization.

  12. Has known uncontrollable pleural effusion, pericardial effusion, and ascites.

  13. Has hemoptysis within 1 month prior to the first dose of study treatment/randomization with a blood volume of ≥2.5 mL every time or expected to require continuous hemostasis therapy during the study treatment.

  14. Has active infections that are poorly controlled by systemic treatment.

  15. Has active tuberculosis.

  16. Known allergy, hypersensitivity or intolerance to IN10018 and/or third-generation EGFR-TKI, or their ingredients.

  17. Pregnant or lactating women.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Experimental Group in cohort 1, cohort 2, and cohort 3

IN10018+Furmonertinib

orally taken once daily

Altri nomi:
  • BI 853520

orally taken once daily

Comparatore attivo: Control Group in cohort 3

Furmonertinib

orally taken once daily

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Recommended phase II dose (RP2D) of IN10018 in combination with third-generation EGFR-TKI in subjects with advanced EGFR mutation-positive NSCLC.
Lasso di tempo: 3 years

Evaluate the number of patients with dose-limited toxicities (DLTs); Determine the RP2D of IN10018 in combination with third-generation EGFR-TKI in subjects with advanced NSCLC.

3 years
ORR of IN10018 in combination with third-generation EGFR-TKI in subjects with advanced EGFR mutation-positive NSCLC.
Lasso di tempo: 3 years

Defined as the proportion of subjects with complete response (CR) or partial response (PR)

3 years
Tumor Shrinkage Rate (TSR) of IN10018 in combination with third-generation EGFR-TKI in cohort 3 of advanced treatment-naive EGFR mutation-positive NSCLC.
Lasso di tempo: 3 years

Defined as the percentage of subjects with the best shrinkage rate of target lesions ≥ 70% and simultaneously with a best response of partial response (PR) or complete response (CR).

3 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
PFS of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.
Lasso di tempo: 3 years

Defined as the time from the first dose of study treatment/randomization to first documentation of disease progression or to death due to any cause, whichever comes first.

3 years
DOR of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.
Lasso di tempo: 3 years

Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first.

3 years
DCR of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.
Lasso di tempo: 3 years

Defined as the proportion of patients with CR, PR, or stable disease (SD).

3 years
OS of IN10018 in combination with third-generation EGFR-TKI in advanced EGFR mutation-positive NSCLC.
Lasso di tempo: 3 years

Defined as the time from the first dose of study treatment/randomization to the date of death due to any cause.

3 years
Number of patients with adverse event
Lasso di tempo: 3 years

The number of participants who experienced AEs is presented.

3 years
PK: AUC of IN10018 following single dose administration and at steady state
Lasso di tempo: 3 years

Area under the concentration-time curve (AUC)

3 years
PK: Cmax of IN10018 following single dose administration and at steady state
Lasso di tempo: 3 years

Maximum concentration (Cmax)

3 years
PK:Ctrough of IN10018 following single dose administration and at steady state
Lasso di tempo: 3 years

Trough concentration (Ctrough)

3 years
PK:Tmax of IN10018 following single dose administration and at steady state
Lasso di tempo: 3 years

Time to Cmax (Tmax)

3 years
PK:t1/2 of IN10018 following single dose administration and at steady state
Lasso di tempo: 3 years

Elimination half-life (t1/2).

3 years
PK:CL/F of IN10018 following single dose administration and at steady state
Lasso di tempo: 3 years

apparent clearance (CL/F)

3 years
PK:Vd/F of IN10018 following single dose administration and at steady state
Lasso di tempo: 3 years

Apparent volume of distribution (Vd/F)

3 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Caicun Zhou, Shanghai Pulmonary Hospital, Shanghai, China

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

13 luglio 2023

Completamento primario (Effettivo)

20 settembre 2025

Completamento dello studio (Stimato)

31 dicembre 2026

Date di iscrizione allo studio

Primo inviato

8 agosto 2023

Primo inviato che soddisfa i criteri di controllo qualità

8 agosto 2023

Primo Inserito (Effettivo)

16 agosto 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

12 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • IN10018-014

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi